.jpeg)
2026-04-27 03:19:03
Cabotegravir Sodium, an advanced integrase strand transfer inhibitor (INSTI), revolutionizes HIV management through its innovative long-acting injectable formulation. Administered every two months, this medication offers a breakthrough in treatment adherence and convenience, particularly for patients requiring flexible regimens.
2026-04-24 06:39:34
Tabrecta (Capmatinib) is an oral targeted drug designed for advanced non-small cell lung cancer (NSCLC) with METex14 skipping mutations. By inhibiting aberrant MET protein, it offers tumor shrinkage and prolonged response, alongside manageable side effects.
2026-04-23 05:36:07
Study reveals pazopanib’s potential in cutaneous angiosarcoma, offering improved survival and manageable safety despite not meeting PFS endpoint.
2026-04-23 05:27:26
A guide to Opicapone (COMT inhibitor) contraindications—identifying critical risks in pheochromocytoma, MAOI combinations, and more. Safeguard treatment with clear usage boundaries.
2026-04-23 05:18:55
Finerenone is a groundbreaking therapy designed for patients with type 2 diabetes and chronic kidney disease. Learn about its mechanism, indications, and cardiovascular benefits in slowing kidney decline and reducing heart risks.
2026-04-22 07:26:16
As a bispecific T cell engager, Tarlatamab revolutionizes cancer treatment by activating immune attacks. This guide outlines unique immune-related adverse events (irAEs) and global management strategies.
2026-04-22 07:18:24
As a 3rd-generation EGFR-targeted therapy, Almonertinib offers significant benefits for NSCLC, but safety management—focused on lung toxicity, skin reactions, cardiac risks, and drug interactions—is crucial for long-term use.
2026-04-21 04:14:58
This article specifies home storage requirements for the oral HSP90 inhibitor Pimitespib, covering temperature, humidity and light protection to maintain drug stability and efficacy, supporting long-term medication management.
2026-04-21 03:28:51
Sirolimus (brand name Rapamune) is a macrolide mTOR immunosuppressant developed by Wyeth. It is mainly used for the prophylaxis of rejection after renal transplantation and the treatment of lymphangioleiomyomatosis. This article systematically introduces its indications, dosage, adverse reactions and safe administration specifications.
2026-04-21 02:57:14
Lusutrombopag is an oral small-molecule thrombopoietin receptor agonist approved by the U.S. FDA in 2018 for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure. This article details its core mechanism of action, standard dosage regimen, and proper drug storage requirements.
2026-04-21 02:42:40
Icotyde (generic name: Icotrokinra) is a medication that works by modulating the immune system. It has a relatively mild overall side effect profile, but still requires close monitoring of drug reactions by patients and healthcare providers. This article details its common side effects and targeted mitigation strategies, core pharmacokinetic characteristics, and standard drug storage requirements.
2026-04-21 02:29:17
Cemiplimab (brand name Libtayo) is a fully human PD-1 immune checkpoint inhibitor developed by Regeneron Pharmaceuticals. Approved by the U.S. FDA in September 2018, it was the first breakthrough therapy for metastatic or locally advanced cutaneous squamous cell carcinoma. By blocking PD-1 ligand binding to activate T-cell anti-tumor activity, it is now approved for the treatment of multiple cancers including cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer.
